###begin article-title 0
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
Cancer cells display widespread changes in DNA methylation that may lead to genetic instability by global hypomethylation and aberrant silencing of tumor suppressor genes by focal hypermethylation. In turn, altered DNA methylation patterns have been used to identify putative tumor suppressor genes.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 51 57 51 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 133 139 133 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 269 275 269 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 503 514 503 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4-eGFP </italic>
In a methylation screening approach, we identified ECRG4 as a differentially methylated gene. We analyzed different cancer cells for ECRG4 promoter methylation by COBRA and bisulfite sequencing. Gene expression analysis was carried out by semi-quantitative RT-PCR. The ECRG4 coding region was cloned and transfected into colorectal carcinoma cells. Cell growth was assessed by MTT and BrdU assays. ECRG4 localization was analyzed by fluorescence microscopy and Western blotting after transfection of an ECRG4-eGFP fusion gene.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 29 35 29 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 122 128 122 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 247 253 247 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 362 371 362 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro </italic>
###xml 445 451 445 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 154 159 <span type="species:ncbi:9606">human</span>
We found a high frequency of ECRG4 promoter methylation in various cancer cell lines. Remarkably, aberrant methylation of ECRG4 was also found in primary human tumor tissues, including samples from colorectal carcinoma and from malignant gliomas. ECRG4 hypermethylation associated strongly with transcriptional silencing and its expression could be re-activated in vitro by demethylating treatment with 5-aza-2'-deoxycytidine. Overexpression of ECRG4 in colorectal carcinoma cells led to a significant decrease in cell growth. In transfected cells, ECRG4 protein was detectable within the Golgi secretion machinery as well as in the culture medium.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 70 75 <span type="species:ncbi:9606">human</span>
ECRG4 is silenced via promoter hypermethylation in different types of human cancer cells. Its gene product may act as inhibitor of cell proliferation in colorectal carcinoma cells and may play a role as extracellular signaling molecule.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 227 228 227 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 391 392 391 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 610 611 610 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 759 760 759 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
Genetic and epigenetic events work in concert to transform a normal cell into a malignant cancer cell. Epigenetic alterations in cancer include changes in chromatin structure and in methylation of cytosine residues in the DNA [1]. In comparison with normal cells, the cancer cell genome is hypomethylated which leads to genomic instability through the activation of mobile genetic elements [2]. Concurrently, CpG-rich regions located in many gene promoters may become hypermethylated. The hypermethylation of these 5'-CpG islands may cause transcriptional silencing of genes, including tumor suppressor genes [3]. Indeed, promoter hypermethylation often acts as second hit in the inactivation of tumor suppressor genes, e.g. when the first allele is deleted [4].
###end p 10
###begin p 11
###xml 207 215 207 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo </italic>
###xml 228 229 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 259 265 259 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DNMT1 </italic>
###xml 379 380 379 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 659 660 659 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 661 662 661 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
The causes of aberrant DNA methylation in cancer are not fully understood. There are hints that overexpression of DNA methyltransferases (DNMTs) may be involved, such as aberrant activity of DNMT3b promoted de novo methylation [5]. Moreover, higher levels of DNMT1 mRNA have been detected in colorectal and stomach cancers as compared to the corresponding non-neoplastic mucosa [6]. Recently, a model has been proposed to explain the phenomenon why some genes become methylated during carcinogenesis while others do not. A targeting mechanism may predispose genes that are repressed by polycomb proteins in normal cells to aberrant DNA methylation in cancer [7,8].
###end p 11
###begin p 12
###xml 83 84 83 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 406 412 406 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIC-1 </italic>
###xml 413 438 413 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hypermethylated in cancer</italic>
###xml 543 545 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 574 580 574 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIC-1 </italic>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 787 789 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 875 877 875 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1030 1032 1030 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 1033 1035 1033 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1091 1093 1091 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
In many tumors, DNA methylation changes tend to accumulate with tumor progression [9]. The profiling of diverse cancer specimens has shown that each tumor type bears a specific DNA methylation pattern. Such a pattern may be used for diagnostic or prognostic purposes [10]. Moreover, aberrant DNA methylation patterns in cancer have been used for the discovery of candidate tumor suppressor genes; e.g. the HIC-1 (hypermethylated in cancer) gene was identified on chromosomal band 17p13.3, which had been described to be aberrantly methylated [11]. Subsequently, the role of HIC-1 in carcinogenesis as a transcriptional repressor has been elucidated [12]. A variety of methods for the genome-wide screening of methylation differences between tumor and normal cells have been established [13] and many aberrantly methylated genes have been identified in different tumor types [14]. As there are additional mechanisms of epigenetic gene regulation, DNA methylation is sometimes not tightly associated with transcriptional silencing [15,16]. Some genes even become repressed upon demethylation [17]. Thus, after identification of a gene differentially methylated in cancer versus normal tissue, its functional role in carcinogenesis remains to be proven by additional molecular and functional analyses.
###end p 12
###begin p 13
###xml 194 200 194 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 378 384 378 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 517 519 517 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 596 602 596 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
In the course of a DNA methylation screening in sarcoma cells using a methylated CpG island amplification coupled with representational difference analysis (MCA-RDA) approach, we identified the ECRG4 gene at 2q12.2 as a gene showing aberrant promoter methylation in tumor but not in normal cells. Previous studies reported on promoter hypermethylation and reduced expression of ECRG4 in advanced esophageal and prostate carcinomas [18,19] and on a tumor suppressor function of ECRG4 in eosophageal cancer cell lines [20]. Here, we report on a further molecular and functional characterization of ECRG4 as a potential tumor suppressor gene in different types of cancer.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Tumor tissue samples
###end title 15
###begin p 16
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 100 108 <span type="species:ncbi:9606">patients</span>
Thirty-one tissue samples of colorectal carcinoma and neighboring normal muscosa were analyzed. All patients and control donors provided their informed oral and written consent. Tumors were diagnosed and surgically removed in the Knappschaftskrankenhaus Bochum-Langendreer, the Universitatsklinik Bergmannsheil Bochum or the Katholisches Krankenhaus Dortmund-West between 1998 and 2003. The surgically removed tumors were classified according to the TNM/UICC system [21].
###end p 16
###begin p 17
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 12 17 <span type="species:ncbi:9606">human</span>
###xml 596 601 <span type="species:ncbi:9606">human</span>
###xml 712 719 <span type="species:ncbi:9606">patient</span>
Seventy-one human glioma tissue samples, including 16 diffuse astrocytomas WHO grade II (A), 15 anaplastic astrocytomas WHO grade III (AA), 10 secondary and 30 primary glioblastomas WHO grade IV (sGBM and pGBM), were collected at the Department of Neuropathology, Heinrich-Heine-University, Dusseldorf. All samples were analyzed in an anonymized manner as approved by the local institutional review boards. Histological classification was performed according to the WHO classification of tumors of the nervous system [22]. As non-neoplastic reference tissue, we used commercially available adult human brain DNA (BD Biosciences, St. Jose, USA) as well as DNA extracted from a cerebral tissue sample of one adult patient who was operated on for a non-neoplastic lesion.
###end p 17
###begin title 18
Methylated CpG island amplification coupled with representational difference analysis (MCA-RDA)
###end title 18
###begin p 19
###xml 52 54 52 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 997 999 996 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 1000 1002 999 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 1039 1045 1038 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 1196 1202 1195 1201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 1317 1319 1316 1318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
###xml 239 247 <span type="species:ncbi:9606">patients</span>
###xml 962 967 <span type="species:ncbi:9606">human</span>
MCA-RDA was carried out according to Toyota et al. [14]. Pooled tumor DNA from three male patients with G3 myxoid-round cell liposarcoma (round cell component > 60%) was used as tester DNA. Pooled genomic DNA from fat tissue of three male patients with non-neoplastic disease was used as driver DNA. Briefly, 5 mug of driver and tester DNA were sequentially digested with SmaI and XmaI. Following adapter ligation, both samples were PCR amplified using FastStart Taq DNA Polymerase (Roche, Mannheim, Germany). Adapter sequences were then removed from the driver and tester amplicon. New adapter sequences were ligated only on the tester amplicon. After two rounds of competitive hybridization and selective amplification, the MCA products were cloned into the pDrive vector (Qiagen, Hilden, Germany). Next, 193 clones were amplified by PCR and analyzed by dot-blot hybridization using an Alu probe. Non-Alu hybridizing inserts were sequenced and mapped onto the human genome using BLAT and BLAST [23,24]. Amongst others, a fragment of the ECRG4 gene, corresponding to a part of intron 1 was cloned (Chr. 2:106682377-106682546; UCSC genome browser, February 2009 built). The genomic region of the ECRG4 gene including 1000 bp upstream of the transcription start site was analyzed for its CpG content using Methprimer [25] and a 413 bp CpG island was identified.
###end p 19
###begin title 20
Cell culture
###end title 20
###begin p 21
###xml 51 52 51 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 204 210 204 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
Eleven tumor cell lines from various tissues (Tab. 1) were obtained from American Type Culture Collection (ATCC, Manassas, USA) and cultured according to standard protocols. To reverse methylation of the ECRG4 promoter, cell lines were treated with 0 to 10 muM 5-aza-2'-deoxycytidine (AZA) for three to four days. In addition, trichostatin A (TSA) treatment was carried out alone or in combination with AZA treatment at a concentration of 1 muM for 24 h. AZA and TSA were purchased from Sigma (Munich, Germany).
###end p 21
###begin p 22
###xml 31 37 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
Cancer cell lines analyzed for ECRG4 hypermethylation and expression
###end p 22
###begin title 23
DNA isolation and sodium bisulfite modification
###end title 23
###begin p 24
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 322 328 322 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M. Sss</italic>
###xml 296 301 <span type="species:ncbi:9606">human</span>
DNA from fresh frozen colorectal tumor tissue samples and from cell lines was isolated with the QIAamp DNA Mini Kit (Qiagen). DNA from glioma tissue samples was extracted by ultracentrifugation over caesium chloride as reported elsewhere [26]. Methylated control DNA was prepared by treatment of human lymphocyte DNA with M. SssI methylase (New England Biolabs, Ipswich, USA). Bisulfite modification of DNA was carried out with the EZ DNA Methylation-Gold Kit (Zymo Research, Orange, USA) according to the manufacturer's instructions.
###end p 24
###begin title 25
Methylation analysis of the ECRG4 promoter region
###end title 25
###begin p 26
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 116 118 116 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1a</xref>
###xml 438 439 438 439 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 499 510 498 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HotStarTaq </italic>
###xml 704 705 691 692 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sub>
###xml 968 970 943 945 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a </sub>
###xml 1080 1084 1049 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BstU</italic>
###xml 1276 1279 1245 1248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Taq</italic>
The ECRG4 promoter region contains a 5'-CpG island covering the promoter region, exon 1 and parts of intron 1 (Fig. 1a). Methylation of an upstream (-353/-136 relative to transcription start site) and a downstream (-69/+187 relative to transcription start site) fragment from this CpG island was determined by COBRA (combined bisulfite and restriction analysis). Unless otherwise stated, all PCR reactions were performed using 1.5 mM MgCl2, 0.2 mM of each dNTP, 0.3 muM of each primer and 0.5 units HotStarTaq DNA polymerase (Qiagen). Following an initial denaturation step for 15 min at 95degreesC, cycling conditions were 40 cycles for 30 s at 95degreesC, 30 s at the specified annealing temperature (Ta) and 30 s at 72degreesC; followed by a final 10 min elongation step at 72degreesC. The upstream promoter region was amplified from sodium bisulfite treated DNA using primers -353: 5'-AGTGGGGGAGTTAAGGAGATATTTT-3' and -136: 5'-CTAAACTCCAAAACCAAAAATACTTAA-3' at a Ta of 63degreesC. The resulting 217 bp product was digested into a 56 bp and a 161 bp product by incubation with BstUI. The downstream promoter region was amplified using primers -69: 5'-GTAGT(C/T)GTTTGGTTTTTAGTTTTT-3' and +187: 5'-CTAAACCCCAACACAAAAACAAA-3' yielding a 256 bp product which was digested with TaqI resulting in a 118 bp and a 138 bp product. Digestion products were separated by polyacrylamide gel electrophoresis (8%) and visualized by ethidium bromide staining. COBRA analysis was carried out at least in duplicate.
###end p 26
###begin p 27
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 0 72 0 72 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>ECRG4 </italic>promoter methylation and expression in different cancer cell lines</bold>
###xml 138 144 138 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 397 403 397 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 550 556 550 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
ECRG4 promoter methylation and expression in different cancer cell lines. a) Schematic representation of the 5'-CpG island located in the ECRG4 promoter region and covering exon 1 as well as parts of intron 1. Primer binding sites are indicated by arrows and labeled with numbers. The transcription start site is marked with +1; the first exon is represented by the grey box. b) COBRA analysis of ECRG4 promoter methylation in various cancer cell lines. The arrow indicates the fragments corresponding to the methylated sequence. c) Re-expression of ECRG4 in SW480 and HCT116 cells following treatment with AZA at different concentrations, either alone or in combination with TSA as indicated in the figure.
###end p 27
###begin p 28
###xml 121 128 121 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pDrive </italic>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
PCR products (upstream fragment) obtained from sodium bisulfite-modified DNA of selected cell lines were cloned into the pDrive vector (Qiagen) and ten individual clones were sequenced. The sequences were analyzed using the BiQ Analyzer program [27]; conversion rates were found to be between 96% and 100%.
###end p 28
###begin p 29
PCR products (downstream fragment) amplified from sodium bisulfite-modified of selected tumor samples were purified and methylation percentages were determined by Epitect sequencing (Qiagen). The Epitect sequencing service includes sequencing of the PCR products using cycle sequencing and modified analysis of raw data to obtain a percentage of methylation for each CpG dinucleotide. Nineteen CpG sites in the promoter fragment were successfully analyzed; the methylation percentages of these sites were averaged to obtain a single methylation score for each sample. Samples with a methylation score three times higher than normal colon tissue were considered as being methylated. As the four analyzed normal colon samples showed an averaged methylation score of 3.7% a methylation score higher than 11.1% was considered as being methylated.
###end p 29
###begin title 30
Analysis of ECRG4 expression by reverse transcription PCR
###end title 30
###begin p 31
###xml 299 305 299 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 455 457 455 457 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a </sub>
###xml 567 573 561 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 695 697 689 691 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a </sub>
###xml 767 778 755 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;-actin </italic>
###xml 910 912 895 897 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a </sub>
###xml 973 979 952 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 1024 1035 1003 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;-actin </italic>
###xml 1313 1318 1289 1294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4</italic>
###xml 1323 1333 1299 1306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#946;-actin</italic>
RNA from fresh frozen colorectal tumor tissues and cell lines was isolated using the NucleoSpin RNA II Kit (Macherey-Nagel, Duren, Germany). One microgram of RNA was reverse transcribed using the Revert Aid H-Minus M-Mulv RT Kit (Fermentas, Vilnius, Lithuania). In the cell lines, a fragment of the ECRG4 cDNA spanning all exons was amplified using primers ECRG4_RT_ for: 5'-GGTTCTCCCTCGCAGCACCT-3' and ECRG4_RT_rev: 5'-CAGCGTGTGGCAAGTCATGGTTAGT-3' at a Ta of 61degreesC (527 bp). As this long fragment was difficult to obtain in tumor samples, a shorter fragment of ECRG4 was amplified using forward primer ECRG4_RT_for2: 5'-GGTACCAGCAGTTTCTCTACATG-3' and the reverse primer stated above at a Ta of 62degreesC (220 bp). As internal control, a 156 bp fragment of the beta-actin gene was amplified using primers ACTIN_RT_for: 5'-TCATGAAGTGTGACGTGGACATC-3' and ACTIN_RT_rev: 5'-CAGGAGGAGCAATGATCTTGATCT-3' at a Ta of 60degreesC. For semiquantitative expression analysis, the ECRG4 RT-PCR was carried out for 33 cycles and the beta-actin RT-PCR for 26 cycles. PCR products were separated on a 2% agarose gel and visualized by ethidium bromide staining. Band intensities (BI) were quantified using the AIDA image analyzer program (Raytest, Straubenhardt, Germany) and relative expression levels were calculated as BI(ECRG4)/BI(beta-actin).
###end p 31
###begin title 32
Cloning of ECRG4 constructs
###end title 32
###begin p 33
###xml 13 19 13 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 335 338 335 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nhe</italic>
###xml 344 347 344 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xba</italic>
###xml 393 399 393 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 608 611 608 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nhe</italic>
###xml 617 621 617 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hind</italic>
The complete ECRG4 coding region was cloned into the pCI Neo vector (Promega, Madison, USA) for transient transfection of cancer cell lines. The coding region was amplified from cDNA of AZA-treated HCT116 cells using primers 5'-gctagCATGGCTGCCTCCCCCGC-3' and 5'-tctagaTTAGTAGTCATCGTAGTTGACGC-3' which contain restriction site tags for NheI and XbaI, respectively (typed in lower letters). The ECRG4 coding region was also cloned into the peGFP-N1 vector (Clontech, Mountain View, USA) with primers 5'-gctagCATGGCTGCCTCCCCCGC-3' and 5'-gctagcATGCTTCAAAAACGAGAAGCACC-3' which contain restriction site tags for NheI and HindIII, respectively. As controls, cells were transfected with the empty vectors.
###end p 33
###begin title 34
Production of ECRG4 containing medium
###end title 34
###begin p 35
###xml 67 69 67 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6 </sup>
For the production of ECRG4 or ECRG4-eGFP containing medium, 2 x 106 HCT116 cells were plated in 10 cm dishes. The next day, cells were transiently transfected with the ECRG4-pCI Neo or ECRG4-eGFP and control vectors, respectively, using 15 mul Attractene (Qiagen) and 4 mug of plasmid DNA. After twenty-four hours, the cell culture medium was replaced with fresh medium without additives. Again twenty-four hours later, the cell culture medium was collected and "Complete" protease inhibitor cocktail (Roche) was added. Cellular debris was removed by centrifugation at 700 g and the medium was concentrated using Amicon-15 centrifugal filter units (Millipore, Billerica, USA). Concentrated medium was used directly or was stored at 4degreesC.
###end p 35
###begin title 36
Cell proliferation assays
###end title 36
###begin p 37
###xml 111 113 111 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 </sup>
Cell growth and viability were evaluated by using BrdU and MTT assays, respectively. For the BrdU assay, 6 x 104 HCT116 or SW480 cells were plated in quadruplicate in 96-well plates. The next day, ECRG4-pCI Neo and control plasmids were transfected using 0.75 mul Attractene (Qiagen) and 0.2 mug of plasmid DNA. Forty-eight hours post transfection, the BrdU assay (BrdU cell proliferation ELISA; Roche) was carried out according to the manufacturer's instructions. For the MTT assay, cells were plated and transfected as described above. Forty-eight hours post transfection, MTT solution (5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide in PBS) was added and cells were incubated for 2 h at 37degreesC. Then 0.04 N HCl in 2-propanol was added and, after 45 min, the absorption was measured photometrically at 550 nm with a background subtraction at 690 nm. For both assays, the mean absorbance values of at least three independent experiments were used for statistical analysis.
###end p 37
###begin p 38
The MTT assay was also carried out after treatment of cells with ECRG4 containing medium and medium from cells transfected with pCI Neo. Therefore, the cells were plated as described. The next day, the cell culture medium was removed and 50 mul of ECRG4 containing medium was added. After 48 hours, the MTT assay was carried out as described.
###end p 38
###begin title 39
Western blot analysis
###end title 39
###begin p 40
For the detection of the ECRG4-eGFP fusion protein, cellular extracts or medium proteins were separated on a 20% SDS-polyacrylamide gel and blotted. Immunodetection was carried out using an eGFP antibody (Abcam, Cambridge, UK) after over night incubation at a dilution of 1:2000 in TBS with 0.1% Tween 20 and 5% skimmed milk powder.
###end p 40
###begin title 41
Fluorescence microscopy
###end title 41
###begin p 42
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4</italic>
For cellular localization of ECRG4-eGFP fusion proteins, cells were grown on cover slips, transiently transfected with the ECRG4-peGFP-N1 or control vectors using 1.5 mul Attractene (Qiagen) and 0.4 mug of plasmid DNA. Beta-1,4-galactosyltransferase (GalT), a Golgi resident protein, was used as Golgi marker. Therefore, a GalT-GFP construct was transfected as described. Forty-eight hours after transfection, cells were counterstained with DAPI and analyzed by fluorescence microscopy at 400-fold magnification.
###end p 42
###begin title 43
Statistical analysis
###end title 43
###begin p 44
Statistical calculations were carried out with the GraphPad QuickCalcs online calculator  and STATISTICA 8 software (StatSoft, Hamburg, Germany). A p-value of less than 0.05 was considered as indicating statistical significance.
###end p 44
###begin title 45
Results
###end title 45
###begin p 46
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 330 336 330 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
To identify newly hypermethylated genes in cancer, we performed a methylated CpG island amplification coupled with representational difference analysis (MCA-RDA) approach, slightly modified to Toyota et al. [14], using soft tissue sarcoma and control tissues (data not shown). Among several candidate sequences, a fragment of the ECRG4 promoter was cloned.
###end p 46
###begin title 47
ECRG4 promoter methylation and expression in tumor cell lines
###end title 47
###begin p 48
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 618 624 618 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 928 930 928 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1b</xref>
###xml 51 56 <span type="species:ncbi:9606">human</span>
To elucidate the role of ECRG4 hypermethylation in human tumor cells, we analyzed the methylation of its promoter in eleven cancer cell lines from colorectal, lung, cervix, hepatocellular and breast carcinoma, fibrosarcoma and glioblastoma (Table 1). COBRA analysis of the upstream promoter fragment showed either full or partial methylation in all cell lines. To confirm these results, sodium bisulfite sequencing of PCR products from HCT116 and SW480 cells was carried out and also showed dense promoter methylation in both colorectal carcinoma lines (data not shown). However, we wondered if the methylation of the ECRG4 promoter extends further downstream towards the transcription start site. We therefore analyzed a second promoter fragment by COBRA and found that all three colorectal carcinoma and all three glioblastoma cell lines, as well as HepG2 and MCF7 were methylated whereas A549, HeLa and HT1080 were not (Fig. 1b).
###end p 48
###begin p 49
###xml 60 66 60 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 103 109 103 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 176 182 176 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1c</xref>
We analyzed the panel of tumor cell lines for expression of ECRG4 using RT-PCR. In these analyses, the ECRG4 transcript was not detected even after 40 cycles of amplification. ECRG4 was re-expressed in the colon cancer cell lines SW480, HCT116, HT-29 and the fibrosarcoma cell line HT1080 after treatment with the demethylating agent AZA. Treatment with TSA alone had no effect. Combined treatment with AZA and TSA induced strong expression (Fig. 1c and data not shown).
###end p 49
###begin title 50
ECRG4 promoter methylation and expression in colon carcinoma
###end title 50
###begin p 51
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 94 100 94 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2a</xref>
###xml 774 776 774 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2b</xref>
###xml 1004 1010 1004 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 1107 1113 1107 1113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 1320 1326 1320 1326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 1434 1436 1434 1436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2c</xref>
As the three analyzed colon cancer cell lines showed ECRG4 hypermethylation, we asked whether ECRG4 methylation also can be found in primary colorectal tumors. We therefore analyzed 31 samples from colon carcinoma and 10 corresponding normal tissues by COBRA (downstream fragment). While tumor samples showed a high methylation frequency (19 of 31; 61%), control tissues lacked detectable methylation (0/10; 0%) (Fisher's exact test; p = 0.023) (Fig. 2a). Results of selected samples were validated using the Epitect Sequencing Service (Qiagen). Eight methylated samples displayed methylation levels ranging from 15% to 79%, seven unmethylated samples showed methylation levels ranging from 2% to 8% and four normal colon tissues showed methylation levels of 3% to 5% (Fig. 2b). Thus, qualitative and semiquantitative methylation analysis revealed a significantly higher methylation frequency in colon carcinoma as compared to neighboring colorectal mucosa (unpaired t-test; p = 0.0166). To determine if ECRG4 promoter methylation is correlated to gene expression, we analyzed relative expression levels of ECRG4 by semiquantitative RT-PCR in eight tumor and nine normal tissues. Of the eight tumor tissues, six were hypermethylated and two were of unknown methylation status. We found significantly lower expression of ECRG4 in tumor tissues as compared to control tissue (BI = 0.33 vs. BI = 1.44; unpaired t-test; p = 0.0018) (Fig. 2c).
###end p 51
###begin p 52
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 0 86 0 86 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>ECRG4 </italic>promoter methylation and mRNA expression in primary colorectal carcinoma samples</bold>
###xml 109 115 109 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 476 482 476 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
ECRG4 promoter methylation and mRNA expression in primary colorectal carcinoma samples. a) COBRA analysis of ECRG4 methylation in colorectal carcinoma and normal colon tissue samples. Arrows point to restriction fragments indicating a methylated sequence. b) Box plots of methylation percentages of selected colorectal carcinomas and normal colon tissue as determined by Epitect bisulfite sequencing analysis. unmeth = unmethylated; meth = methylated c) Box plots of relative ECRG4 mRNA expression as determined by semiquantitative RT-PCR in colorectal carcinomas relative to normal colon tissue. Note a significantly lower expression in tumor tissue (p = 0.0018). NT = normal colon tissue; CC = colorectal carcinoma.
###end p 52
###begin title 53
ECRG4 promoter methylation in glioma
###end title 53
###begin p 54
###xml 59 65 59 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 236 242 236 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 257 258 257 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3</xref>
###xml 323 329 323 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 386 392 386 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
Next, we analyzed 71 glioma samples for methylation of the ECRG4 promoter by COBRA. Seven out of 31 diffuse or anaplastic astrocytomas (23%), 12 out of 30 primary (40%) and 9 out of 10 secondary (90%) glioblastomas carried a methylated ECRG4 promoter (Fig. 3). In contrast, the two investigated normal brain samples lacked ECRG4 promoter methylation. Statistical analysis revealed that ECRG4 methylation was significantly more frequent in secondary glioblastomas as compared to diffuse and anaplastic astrocytomas or primary glioblastomas (Fisher's exact test; p = 0.0003 and p = 0.0094, respectively).
###end p 54
###begin p 55
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 0 59 0 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>ECRG4 </italic>promoter methylation in primary glioma tissue samples</bold>
###xml 79 85 79 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
ECRG4 promoter methylation in primary glioma tissue samples. COBRA analysis of ECRG4 methylation in astrocytic gliomas of different WHO grades and two non-neoplastic brain samples (NB1, NB2). Representative data from 49 samples are shown. Arrows point to restriction fragments indicating a methylated sequence. The diagnosis is given in the subheadings. The tumor numbers are provided on top of each lane.
###end p 55
###begin title 56
Effect of ECRG4 protein on colorectal carcinoma cell proliferation
###end title 56
###begin p 57
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4</italic>
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 216 222 216 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 406 408 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4a</xref>
###xml 456 462 454 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 624 626 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4b</xref>
###xml 1042 1044 1032 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4c</xref>
###xml 1083 1089 1073 1079 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
To evaluate the cellular effects of re-expression of ECRG4, we cloned the ECRG4 coding region and transiently transfected the gene into the colorectal carcinoma cell lines HCT116 and SW480. The proliferation rate of ECRG4 transfected HCT116 cells, as assessed by the BrdU assay, was significantly reduced to 33% (+/- 13%; one sample t-test; p = 0.0133) relative to the mock-transfected control cells (Fig. 4a). In the MTT assay, relative cell viability of ECRG4 transfected HCT116 and SW480 cells was significantly reduced to 33% (+/- 9%; one sample t-test; p = 0.0005) and 74% (+/- 1%; one sample t-test; p = 0.0003) (Fig. 4b), respectively. To eliminate the influence of the transfection on tumor cell growth, we measured cell viability after treatment of cells with ECRG4 containing medium and medium from transfection with pCI Neo. Again, ECRG4 treated HCT116 and SW480 cells showed a reduced cell viability relative to control treated cells (60% +/- 18%; one sample t-test; p = 0.0603) (54% +/- 16%; one sample t-test; p = 0.0397) (Fig. 4c). Thus, re-expression of the silenced ECRG4 gene as well as treatment of cells with ECRG4 protein significantly reduced colon cancer cell growth.
###end p 57
###begin p 58
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 0 111 0 111 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Effects of <italic>ECRG4 </italic>overexpression or ECRG4 treatment in colorectal carcinoma cells on proliferation and viability</bold>
###xml 146 152 146 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 315 321 315 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
Effects of ECRG4 overexpression or ECRG4 treatment in colorectal carcinoma cells on proliferation and viability. a) Reduced proliferation rate of ECRG4 transfected HCT116 and SW480 cells relative to control cells as determined by the BrdU assay (n = 3; p = 0.0133) (n = 3; p = 0.0775). b) Reduced cell viability of ECRG4 transfected HCT116 and SW480 cells relative to control cells as determined by the MTT assay (n = 4; p = 0.0005) (n = 3; p = 0.0003). c) Reduced cell viability of HCT116 and SW480 cells treated with ECRG4-containing medium relative to cells treated with medium from pCI Neo transfection as determined by the MTT assay (n = 3; p = 0.0603) (n = 3; p = 0.0397).
###end p 58
###begin title 59
Localization of ECRG4 in cultured colorectal carcinoma cells
###end title 59
###begin p 60
###xml 152 163 152 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4-eGFP </italic>
###xml 413 415 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5a</xref>
Finally, we analyzed the subcellular localization of the ECRG4 protein and its possible secretion into the culture medium. Therefore, we transfected an ECRG4-eGFP fusion gene into HCT116 cells. The cell culture medium was collected 48 h post-transfection and concentrated. Western Blotting with an eGFP antibody detected the ECRG4-eGFP fusion protein as three distinct bands of ~40 kDa, ~35 kDa and ~28 kDa (Fig. 5a). The highest molecular weight (MW) band would fit to the MW of the ECRG4-eGFP fusion protein (eGFP: 26 kDa + ECRG4 without signal peptide: 14 kDa). The lower MW bands presumably represented ECRG4-eGFP proteins with N-terminally processed ECRG4.
###end p 60
###begin p 61
###xml 0 73 0 73 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Extracellular secretion and subcellular localization of the ECRG4 protein</bold>
Extracellular secretion and subcellular localization of the ECRG4 protein. a) Western Blot analysis with an anti-GFP antibody of concentrated cell culture medium of ECRG4-eGFP transfected HCT116 cells shows that ECRG4 is secreted. 1 = concentrated medium of non-transfected cells; 2 = total lysate of eGFP transfected cells; 3 = concentrated medium of ECRG4-eGFP transfected cells. Arrows point to three different processed forms of the ECRG4-eGFP fusion protein. b) Fluorescence microscopy analysis of HCT116 cells transfected with eGFP, ECRG4-eGFP and GalT-GFP vectors. Note that transfection with the eGFP control vector leads to homogenous staining, whereas cells transfected with the ECRG4 fusion gene show staining of discrete structures. These structures are also stained after transfection of the GFP tagged Golgi marker galactosyltransferase (GalT-GFP).
###end p 61
###begin p 62
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5b</xref>
We also analyzed the intracellular localization of ECRG4 by fluorescence microscopy after transfection of the fusion gene. Whereas cells transfected with the eGFP vector control showed homogenous staining all over the cell, the ECRG4-eGFP transfected cells displayed discrete staining localized in close proximity to the nucleus (Fig. 5b). This staining pattern was also obtained after transfection of cells with a GFP tagged construct of the golgi resident protein beta-1,4-galactosyltransferase. Thus, it could be concluded that ECRG4 was localized to the Golgi apparatus which would be in accordance with the secretory pathway of proteins.
###end p 62
###begin title 63
Discussion and Conclusions
###end title 63
###begin p 64
###xml 42 48 42 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 727 729 727 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 206 211 <span type="species:ncbi:9606">human</span>
The data reported in this study implicate ECRG4 as a candidate tumor suppressor gene at 2q12.2 that is frequently hypermethylated and transcriptionally down-regulated in colon carcinomas and other types of human cancers. Cancer cells are characterized by extensive epigenetic DNA alterations, including global hypomethylation as well as focal hypermethylation at CpG islands in gene promoters. DNA hypermethylation constitutes a major cause of aberrant gene silencing in cancer [28]. However, not all aberrantly silenced genes also play functional roles in tumor development. In analogy to somatic mutations in tumor cells, which in part are neutral passenger mutations, some methylation events might be epigenetic passengers [29]. Therefore, each candidate tumor suppressor gene identified by methylation screening methods has to be carefully evaluated for its role in tumor development and progression.
###end p 64
###begin p 65
###xml 65 71 65 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 151 157 151 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 316 322 316 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 442 448 442 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 257 262 <span type="species:ncbi:9606">human</span>
In the course of a methylation screening approach, we identified ECRG4 as a gene differentially methylated in sarcoma versus normal cells. Previously, ECRG4 had been found to be hypermethylated in esophageal cancer [30]. To investigate its possible role in human cancer, we (1) analyzed different tumor entities for ECRG4 promoter methylation, (2) revealed a correlation between the methylation and gene silencing, (3) measured the effect of ECRG4 re-expression on the proliferation of colon cancer cells, and (4) determined the cellular localization of the ECRG4 protein.
###end p 65
###begin p 66
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 699 705 699 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 816 818 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 819 821 819 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 849 855 849 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 913 919 913 919 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 973 979 973 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 1114 1121 1114 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RASSF1A</italic>
###xml 1245 1247 1245 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 95 100 <span type="species:ncbi:9606">human</span>
###xml 806 814 <span type="species:ncbi:9606">patients</span>
Initially, we found the ECRG4 promoter to be frequently hypermethylated in a broad spectrum of human tumor cell lines. To exclude that hypermethylation is limited to tumor cells in culture we carried out qualitative and semiquantitative methylation analysis of primary cancer samples. In colorectal carcinomas, we found a high frequency of methylation, but, as the analyzed samples were all from advanced staged tumors, correlations to clinical features were not possible. We also found frequent methylation in astrocytic gliomas, in which the methylation frequency increased with advancing tumor grade, being particularly common in glioblastomas. This result is consistent with recent reports that ECRG4 methylation is associated with advanced disease and poor prognosis in esophageal and prostate cancer patients [18,31]. Our findings of frequent ECRG4 methylation in various cancer cell lines may suggest that ECRG4 might be methylated in even other tumor types. Hence, ECRG4 might belong to the set of genes that are frequently methylated in multiple types of cancer. Another example is the pro-apoptotic gene RASSF1A, which is rarely mutated but often hypermethylated in various kinds of epithelial, mesenchymal and neuroectodermal tumors [32]. Such genes often regulate processes that are crucial for cancer development, such as apoptosis or cell cycle progression.
###end p 66
###begin p 67
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 169 175 169 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 225 231 225 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 343 349 343 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 500 506 500 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 652 658 652 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 741 747 741 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 883 885 883 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 886 888 886 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
Our data also indicate that ECRG4 promoter methylation strongly correlates with transcriptional silencing. None of the methylated cancer cell lines showed expression of ECRG4 transcripts. Furthermore, the expression level of ECRG4 was significantly lower in colon cancer samples than in normal mucosa, which agrees with the recent result that ECRG4 expression is lower in esophageal cancer than in surrounding normal epithelium [19]. It should be noted that two normal colon tissues also showed weak ECRG4 expression. This could be due to a methylation field effect in normal tissue surrounding tumor tissue. Alternatively, it cannot be ruled out that ECRG4 silencing might be regulated by other mechanisms than DNA methylation. Then again, ECRG4 expression could be reactivated by demethylating treatment, which is a known feature of epigenetically silenced tumor suppressor genes [33,34].
###end p 67
###begin p 68
###xml 3 9 3 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 240 246 240 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 370 376 370 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 526 534 526 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo </italic>
###xml 672 674 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
By ECRG4 overexpression or ECRG4 treatment, we demonstrate an inhibitory effect of this protein on colorectal carcinoma cell growth. Using two independent assays of cell viability and cell proliferation, we found reduced growth rates after ECRG4 transfection or culturing of cells in ECRG4 containing medium. An additional hint supporting a growth suppressive effect of ECRG4 in tumor cells comes from stabile transfection experiments, in which we observed that the expression of the transgene rapidly declined, presumably by de novo methylation (data not shown). Recent findings show that ECRG4 acts as a tumor suppressor in esophageal cancer cells in vitro and in vivo [20]. Our data provide first hints that ECRG4 may serve a tumor suppressor function also in colorectal carcinoma cells.
###end p 68
###begin p 69
###xml 62 68 62 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 253 255 253 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 786 788 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 1031 1037 1031 1037 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 1152 1154 1152 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 1155 1157 1155 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 233 238 <span type="species:ncbi:10090">mouse</span>
###xml 944 950 <span type="species:ncbi:10090">murine</span>
Finally, we demonstrate that ECRG4 is a secreted protein. The ECRG4 gene codes for a small protein of 148 aa (17 kDa) of yet unknown function and without significant homology to other known proteins, except for a 31% homology to the mouse IgG V region [19]. A putative N-terminal signal peptide suggests that ECRG4 might be a secreted protein. We found that an ECRG4-eGFP fusion protein localized to the Golgi apparatus within the cell, which would be consistent with the secretory pathway of proteins. In addition, we detected the ECRG4-eGFP fusion protein in the cell culture medium of transfected cells. Recently, the ECRG4 protein was renamed in the Uniprot database  as "augurin", a protein which had been identified in a bioinformatics approach as a putative new peptide hormone [35]. Mirabeau et al. showed that augurin is a secreted protein which is processed from its prepro-form. However, only limited augurin expression was found in murine endocrine tissues. In addition to its potential expression in endocrine glands, ECRG4 is expressed in normal epithelium of the colon and esophagus and in fat tissue as shown here and in other studies [18,19]. The findings of Mirabeau et al. (2007) support the hypothesis that ECRG4 functions as an extracellular signaling molecule. Interestingly, unlike other peptide hormones, the signaling of ECRG4 is not growth promoting but rather growth limiting.
###end p 69
###begin p 70
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4 </italic>
###xml 279 288 279 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro </italic>
###xml 89 94 <span type="species:ncbi:9606">human</span>
In conclusion, we show that the ECRG4 gene is frequently hypermethylated in a variety of human cancer cells. Hypermethylation associates strongly with transcriptional silencing in colorectal carcinomas. Furthermore, ECRG4 displays growth-inhibitory effects on colon cancer cells in vitro and may function as a secreted extracellular signaling molecule. Thus, restoring ECRG4 expression in the tumor, either by epigenetic therapy or application of recombinant protein, may represent a promising novel therapeutic approach in various types of cancers.
###end p 70
###begin title 71
Abbreviations
###end title 71
###begin p 72
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ECRG4</italic>
AZA: 5-aza-2'-deoxycytidine; ECRG4: esophageal cancer related gene 4; TSA: trichostatin A;
###end p 72
###begin title 73
Competing interests
###end title 73
###begin p 74
The authors declare that they have no competing interests.
###end p 74
###begin title 75
Authors' contributions
###end title 75
###begin p 76
SG carried out the DNA methylation and gene expression studies and drafted the manuscript, VF carried out the cloning and the functional characterization experiments, TT analyzed colon carcinoma samples, MW and GR analyzed and interpreted the results of the glioblastoma samples and drafted the manuscript, AT analyzed colon carcinoma samples and drafted the manuscript, CK and DM analyzed colon carcinoma samples, OM participated in the design of the study and drafted the manuscript, SS conceived of the study, participated in its design and coordination and drafted the manuscript. All authors read and approved the final manuscript.
###end p 76
###begin title 77
Pre-publication history
###end title 77
###begin p 78
The pre-publication history for this paper can be accessed here:
###end p 78
###begin p 79

###end p 79
###begin title 80
Acknowledgements
###end title 80
###begin p 81
This work was supported by a Tandem project of the Max Planck Society. We thank Anchal Chandra for providing the GalT construct.
###end p 81
###begin article-title 82
The fundamental role of epigenetic events in cancer
###end article-title 82
###begin article-title 83
###xml 73 78 <span type="species:ncbi:9606">Human</span>
Chromosomal Instability Correlates with Genome-wide DNA Demethylation in Human Primary Colorectal Cancers
###end article-title 83
###begin article-title 84
Cancer epigenetics comes of age
###end article-title 84
###begin article-title 85
Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer
###end article-title 85
###begin article-title 86
Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing
###end article-title 86
###begin article-title 87
###xml 110 115 <span type="species:ncbi:9606">human</span>
DNA methyltransferase expression and DNA methylation of CPG islands and peri-centromeric satellite regions in human colorectal and stomach cancers
###end article-title 87
###begin article-title 88
Epigenetic stem cell signature in cancer
###end article-title 88
###begin article-title 89
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing
###end article-title 89
###begin article-title 90
###xml 90 95 <span type="species:ncbi:9606">human</span>
Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state
###end article-title 90
###begin article-title 91
###xml 35 40 <span type="species:ncbi:9606">human</span>
A gene hypermethylation profile of human cancer
###end article-title 91
###begin article-title 92
p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3
###end article-title 92
###begin article-title 93
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors
###end article-title 93
###begin article-title 94
Detection and interpretation of altered methylation patterns in cancer cells
###end article-title 94
###begin article-title 95
Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification
###end article-title 95
###begin article-title 96
Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach
###end article-title 96
###begin article-title 97
###xml 82 87 <span type="species:ncbi:9606">human</span>
Differentially expressed genes are marked by histone 3 lysine 9 trimethylation in human cancer cells
###end article-title 97
###begin article-title 98
Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms
###end article-title 98
###begin article-title 99
Hypermethylation of Genes for Diagnosis and Risk Stratification of Prostate Cancer
###end article-title 99
###begin article-title 100
###xml 109 114 <span type="species:ncbi:9606">human</span>
Expression of ECRG4, a novel esophageal cancer-related gene, downregulated by CpG island hypermethylation in human esophageal squamous cell carcinoma
###end article-title 100
###begin article-title 101
Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo
###end article-title 101
###begin article-title 102
The 2007 WHO classification of tumours of the central nervous system
###end article-title 102
###begin article-title 103
Basic local alignment search tool
###end article-title 103
###begin article-title 104
BLAT--the BLAST-like alignment tool
###end article-title 104
###begin article-title 105
MethPrimer: designing primers for methylation PCRs
###end article-title 105
###begin article-title 106
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: MR imaging findings at different ages--3rd-6th decades
###end article-title 106
###begin article-title 107
BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing
###end article-title 107
###begin article-title 108
Epigenetic gene silencing in cancer: the DNA hypermethylome
###end article-title 108
###begin article-title 109
###xml 32 37 <span type="species:ncbi:9606">human</span>
Patterns of somatic mutation in human cancer genomes
###end article-title 109
###begin article-title 110
###xml 57 62 <span type="species:ncbi:9606">human</span>
[Cloning and identification of cDNA fragments related to human esophageal cancer]
###end article-title 110
###begin article-title 111
###xml 77 85 <span type="species:ncbi:9606">patients</span>
Expression of ECRG4 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma
###end article-title 111
###begin article-title 112
The RASSF1A tumor suppressor
###end article-title 112
###begin article-title 113
Dormant hypermethylated tumour suppressor genes: questions and answers
###end article-title 113
###begin article-title 114
Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications
###end article-title 114
###begin article-title 115
###xml 48 53 <span type="species:ncbi:9606">human</span>
Identification of novel peptide hormones in the human proteome by hidden Markov model screening
###end article-title 115
###begin article-title 116
###xml 36 41 <span type="species:ncbi:9606">human</span>
A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells
###end article-title 116
###begin article-title 117
###xml 40 45 <span type="species:ncbi:9606">human</span>
Heterogeneity of malignant cells from a human colonic carcinoma
###end article-title 117
###begin article-title 118
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen
###end article-title 118
###begin article-title 119
###xml 66 71 <span type="species:ncbi:9606">human</span>
Absence of HeLa cell contamination in 169 cell lines derived from human tumors
###end article-title 119
###begin article-title 120
###xml 66 71 <span type="species:ncbi:9606">human</span>
Intercellular karyotypic similarity in near-diploid cell lines of human tumor origins
###end article-title 120
###begin article-title 121
###xml 2 7 <span type="species:ncbi:9606">human</span>
A human cell line from a pleural effusion derived from a breast carcinoma
###end article-title 121
###begin article-title 122
###xml 18 23 <span type="species:ncbi:9606">human</span>
Classification of human colorectal adenocarcinoma cell lines
###end article-title 122
###begin article-title 123
###xml 43 48 <span type="species:ncbi:9606">human</span>
Long term culture of normal and neoplastic human glia
###end article-title 123
###begin article-title 124
###xml 31 36 <span type="species:ncbi:9606">human</span>
T98G: an anchorage-independent human tumor cell line that exhibits stationary phase G1 arrest in vitro
###end article-title 124

